CCM
PCRX icon

Cadian Capital Management’s Pacira BioSciences PCRX Stock Holding History

Cadian Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-615,000
Closed -$28M – 45
2017
Q1 		$28M Buy
+615,000
New +$26.6M 1.34% 25

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Cadian Capital Management's PCRX Position: Q2 2017 in Review

Cadian Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 615,000 shares — an estimated $28M sold.

Cadian Capital Management first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $28M in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Cadian Capital Management reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Cadian Capital Management sold 615,000 Pacira BioSciences shares in Q2 2017, an estimated $28M.
  • Cadian Capital Management first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
  • Cadian Capital Management's Pacira BioSciences position peaked at $28M in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Cadian Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.